Abstract: A prophylactic and therapeutic agent is provided for the prevention and treatment of cataracts. The agent is comprised of glutathione monoalkyl esters such as, isopropyl.gamma.-L-glutamyl-L-cysteinyl glycinate sulfate, and a pharmaceutically acceptable carrier.

Abstract: Methods and compositions for the treatment of inflammatory bowel diseases, chemically-induced irritation and inflammation, and other irritative or inflammatory conditions utilizing the peptide sequences Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, or derivatives or salts thereof are disclosed.

Abstract: All isomeric forms and mixtures of isomers of glutamic acid compounds of the formula ##STR1## wherein the glutamic acid of D- or L- configuration, R.sub.1 is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, an amino acid, a peptide of 2 to 4 amino acids and an amino acid or a peptide of 2 to 4 amino acids in which the amine is esterified with an optionally unsaturated aliphatic carboxylic acid of 6 to 24 carbon atoms or R.sub.1 is selected from the group consisting of a residue of a C.sub.6 -C.sub.24 optionally unsaturated aliphatic acid, R.sub.5 is selected from the group consisting of hydrogen or an alkyl radical of 1 to 5 carbon atoms, R.sub.3 is selected from the group consisting of hydroxy, alkoxy of 1 to 5 carbon atoms, an amino acid with the amine optionally substituted with alkyl of 1 to 5 carbon atoms, Z is ##STR2## R.sub.2 is selected from the group consisting of hydrogen, an amino acid and a peptide of 2 to 4 amino acids, R.sub.

Abstract: Several known members of the corticotropin releasing factor (CRF) family have been synthesized and tested, including human and rat CRF which have the formula: H-Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His- Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Ala-Arg-Ala-Glu-Gln- Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu- Ile-Ile-NH.sub.2. Peptides are herein disclosed that are potent competitive antagonists of CRF in mammals. One which has been found to be particularly potent is: H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala- Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn- Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH.sub.2. One that has shown particularly prolonged duration of potency is: H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala- Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn- Arg-Lys-CML-Nle-Glu-Ile-Ile-NH.sub.2.

Abstract: The invention is new renin inhibitor dipeptide and tripeptide derivatives of the formula: ##STR1##

Abstract: The present invention relates to a method for the detection in body fluids of antibodies to hepatitis C virus (HCV), also known as a non-A non-B hepatitis (NANBH) virus and to the diagnosis of NANBH by the use of a composition of synthetic peptides. Each of these peptides has an amino acid sequence corresponding to immunodominant regions of a fusion protein and a non-structural polypeptide of HCV, SOD/HCV C100 and a postulated HCV structural (core) protein. More specifically, the present invention is directed to the use of a group of synthetic peptides in a prescribed sequence or their analogues for the detection of antibodies to HCV in body fluids. The detection method includes an enzyme-linked immunosorbent assay (ELISA), and other forms of immunoassay procedures.

Abstract: A bone cement is disclosed wherein the liquid component contains a therapeutic or diagnostic substance in combination with an emulsifying agent for said substance.

Abstract: Erythropoietin (EPO) peptides and the use thereof for preparing epitope-specific anti-EPO antibodies are described. Also described are corresponding anti-EPO antibodies which take the form of polyclonal antibodies (antisera) or of monoclonal antibodies. These antibodies are suitable for purifying EPO, EPO derivatives or EPO peptides. The epitope-specific anti-EPO antibodies according to the invention can also be used for the detection of EPO and, in particular, for the epitope-specific detection of EPO. Additionally described are anti-idiotype antibodies which imitate a receptor region of EPO. Finally, pharmaceuticals which contain the said EPO peptides, anti-EPO antibodies or anti-idiotype antibodies, and diagnostic aids for the detection of EPO or of anti-EPO antibodies, are described.

Abstract: A method is provided for inhibiting growth of cancer cells comprising contacting said cells with an effective growth-inhibiting amount of a compound of the formula (II): ##STR1## or a physiologically acceptable salt thereof, wherein A.sup.1 and A.sup.2 are individually L-amino acid residues selected from the group consisting of Ala, Pro, Gly, Glu, Leu, Lys, Phe, Ser, Val, Ile, Arg, Tyr, Thr, Asp, Asn and Gly; R.sup.1 is C.sub.1 -C.sub.6 (alkyl) which is unsubstituted or is substituted with an aromatic substituent or one or more in-chain bivalent groups selected from the group consisting of --O--, --CO--, --S--, --NH--, --CONH--, CH.dbd.CH--, and --SO.sub.2 --; Y.sup.1 and Y.sup.2 are each H, or taken together from a moiety derived from a dihydroxy compound, and R.sup.1 is H or an N-terminal protecting group.

Abstract: Novel blood coagulation inhibitors are disclosed which are peptide fragments comprising (A) Kunitz-type domain two of lipoprotein-associated coagulation inhibitor which inhibits Factor Xa production and (B) Kunitz-type domains one and two of lipoprotein-associated coagulation inhibitor which inhibits Factor VIIa/TF enzymatic complex formation.

Abstract: Novel antiviral peptides are disclosed which have a sequence of about 6 to 30 amino acids and which are substantially identical to a small portion of a glycoprotein in a virus that contains a lipid-bilayer in its structure. A preferred peptide having antiviral activity against influenza virus is the decapeptide amide N-G-S-L-Q-C-R-I-C-I-NH.sub.2 [SEQ ID NO:3].

Abstract: A novel arthropodicidally-active composition-of-matter is disclosed. Such a composition-of-matter comprises an aqueous lower alkanol solvent, and a toxicant as well as an emulsifier, both contained within the solvent. The amount of emulsifier, relative to the amount of solvent, is effective for forming a foam matrix that is able to collapse after a predetermined period of time thereby to form an arthropodicidally-active film. Also disclosed are methods for producing such an arthropodicidally-active film.

Abstract: Homogeneous, stable liquid compositions are provided comprising a carrier, e.g., a plasticizer, a solvent selected from C.sub.5 to C.sub.9 aliphatic alcohols and diols, e.g., isodecyl alcohol, 2-ethyl hexanol, 2-ethyl-1, 3-hexanediol or mixtures thereof, and a microbiocidal compound soluble in said solvent wherein the microbiocidal compound is present in amounts greater than 2.5 percent by weight of the combined weight of carrier, solvent and microbiocidal compound.

Abstract: The cysteine-containing polypeptide is oxidized with hydrogen peroxide to produce the biologically active polypeptide having the intramolecular disulfide bridge.

Abstract: Nutrient compositions useful as amino acid infusions comprise L-glutamyl-L-cystine and/or L-glutamyl-L-cysteine disulfide. The nutrient compositions can achieve extremely high utilization of cysteine and cystine which could not be hitherto used as nutrient compositions.

Abstract: Compositions for delaying the progression from AIDS to ARC, and for alleviating symptoms of AIDS and ARC are disclosed together with clinical results of use of such compositions in clinical trials with of actual human patients suffering from these diseases. The compositions are based on a Tyr-Gly amino acid residue sequence. Typical dosage amounts are in the range of femtomoles/kg of body weight.

Abstract: A new lipase and a new protease, which can be produced by a new Pseudomonas strain, and methods of producing such lipase and protease using said strain, protease, or producing enzymatic additives for detergents whose main active component is the lipase of the invention. Further disclosed are detergent washing compositions containing the lipase and/or the protease or the enzymatic additives, and a washing process using said compositions.

Abstract: A peptide of formula (I):A-B-C-D-Gln-Trp-Ala-Val-X-Y-T-W (I)wherein either:(i) A represents a hydrogen atom, a Boc group or an acetyl group, one of B and C represents a pMel or mMel residue, and the other of B and C represents a sigma bond or a Gly, Leu-Gly, E-Leu-Gly or Gln-E-Leu-Gly, E, or E-Gly residue with E=Arg(A), arg(A), Lys(A), lys(A), Orn(A) and orn(A); or(ii) A represents a hydrogen atom;B represents a Glp-Arg-Leu-Gly residue;C represents a pMel or mMel residue;D represents a sigma bond or an Asn or Thr residue;X represents a Gly or ala residue;Y represents a sigma bond or a His(R.sub.1);his(R.sub.1), Phe, phe, Ser, ser, Ala or ala residue,T represents a sigma bond or a Leu, leu, Phe or phe residue;W represents an OH, amino, pentylamino or phenethyl-amino group or a Met-R.sub.2, Leu-R.sub.2, Ile-R.sub.2 or Nle-R.sub.2 residue;R.sub.1 represents a hydrogen atom or a Tos, Dnp or Bzl group; andR.sub.

Abstract: New peptide derivatives of which utility in the treatment of such diseases as rheumatoid arthritis, peridental diseases, corneal ulcer and epidermolysis bullosa is expected. These compounds are hydroxamic acid derivatives of tetrapeptides having a specific inhibitory activity against collagenase derived from vertebrates.

Abstract: This invention relates to synergistic biocide compositions having decreased sensitization potential.